Euro vs US Dollar

Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

Registrieren

OGN

Organon (OGN)

Organon and Co

Von:

Regulatory News

Text Search:

Sortieren nach:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:OGN

1 2 3 4 5 6 7 8 9 10 Next >>

Datum	Zeit	Quelle	Überschrift	Symbol	Firma
02/05/2024	13h30	Business Wire	Organon Reports Results for the First Quarter Ended March 31, 2024	NYSE:OGN	Organon and Co
09/04/2024	14h13	Business Wire	Prolia ® とXgeva ® （デノスマブ）との第3相比較臨床試験でバイオシミラー候補HLX14が主要評価項目を達成	NYSE:OGN	Organon and Co
08/04/2024	20h31	Business Wire	Klinische Phase-3-Vergleichsstudie zwischen Prolia ® und Xgeva ® (Denosumab) - Biosimilar-Kandidat HLX14 erreicht primäre Endpunkte	NYSE:OGN	Organon and Co
08/04/2024	20h31	Business Wire	L'essai clinique comparatif de phase 3 du candidat biosimilaire de Prolia ® et de Xgeva ® (denosumab) HLX14 remplit les critères d'évaluation primaires	NYSE:OGN	Organon and Co
08/04/2024	12h15	Business Wire	Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024	NYSE:OGN	Organon and Co
08/04/2024	12h00	Business Wire	Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints	NYSE:OGN	Organon and Co
08/03/2024	15h01	PR Newswire (Canada)	On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's health	NYSE:OGN	Organon and Co
08/03/2024	15h01	PR Newswire (Canada)	À l'occasion de la Journée internationale des femmes, Organon Canada encourage les entreprises à Investir en elle et à lutter contre les inégalités entre les genres par la santé des femmes	NYSE:OGN	Organon and Co
01/03/2024	22h24	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:OGN	Organon and Co
01/03/2024	22h24	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:OGN	Organon and Co
01/03/2024	22h22	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:OGN	Organon and Co
01/03/2024	22h22	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:OGN	Organon and Co
26/02/2024	14h10	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NYSE:OGN	Organon and Co
23/02/2024	17h46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:OGN	Organon and Co
20/02/2024	14h00	Business Wire	Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary	NYSE:OGN	Organon and Co
15/02/2024	13h48	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:OGN	Organon and Co
15/02/2024	13h30	Business Wire	Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023	NYSE:OGN	Organon and Co
13/02/2024	22h16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:OGN	Organon and Co
01/02/2024	13h30	Business Wire	Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024	NYSE:OGN	Organon and Co
10/01/2024	13h33	Business Wire	Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older	NYSE:OGN	Organon and Co
08/01/2024	13h30	Business Wire	Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook	NYSE:OGN	Organon and Co
21/12/2023	13h30	Business Wire	Organon To Present at the 42nd Annual J.P. Morgan Healthcare Conference	NYSE:OGN	Organon and Co
19/12/2023	14h30	Business Wire	Organon et Lilly concluent un accord de commercialisation en Europe pour deux médicaments contre la migraine	NYSE:OGN	Organon and Co
19/12/2023	10h11	Business Wire	Organon と Lilly、ヨーロッパで 2 種類の片頭痛薬商業化契約を締結	NYSE:OGN	Organon and Co
19/12/2023	03h26	Business Wire	Organon und Lilly schließen Vermarktungsvereinbarung für zwei Migräne-Medikamente in Europa	NYSE:OGN	Organon and Co
18/12/2023	13h30	Business Wire	Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines	NYSE:OGN	Organon and Co
05/12/2023	22h31	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:OGN	Organon and Co
21/11/2023	13h30	Business Wire	Organon To Present at the Piper Sandler 35th Annual Healthcare Conference	NYSE:OGN	Organon and Co
07/11/2023	22h15	GlobeNewswire Inc.	Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira®	NYSE:OGN	Organon and Co
03/11/2023	12h52	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NYSE:OGN	Organon and Co

Showing the most relevant articles for your search:NYSE:OGN

1 2 3 4 5 6 7 8 9 10 Next >>

Health Care Select Sector

Deutsche Telekom (QX)

Deutsche Lufthansa

Euro vs Sterling

BNP Paribas (QX)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen